Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Assets (2019 - 2025)

Silence Therapeutics' Non-Current Assets history spans 7 years, with the latest figure at $12.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 16.27% year-over-year to $12.8 million; the TTM value through Jun 2025 reached $16.7 million, changed N/A, while the annual FY2025 figure was $12.8 million, 16.27% down from the prior year.
  • Non-Current Assets for Q4 2025 was $12.8 million at Silence Therapeutics, down from $13.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $16.7 million in Q2 2025 and bottomed at $12.7 million in Q4 2022.
  • The 5-year median for Non-Current Assets is $14.3 million (2024), against an average of $14.4 million.
  • The largest annual shift saw Non-Current Assets increased 25.26% in 2023 before it decreased 16.27% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $13.3 million in 2021, then fell by 4.58% to $12.7 million in 2022, then increased by 25.26% to $15.9 million in 2023, then dropped by 3.9% to $15.3 million in 2024, then fell by 16.27% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Non-Current Assets are $12.8 million (Q4 2025), $13.2 million (Q3 2025), and $16.7 million (Q2 2025).